الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 83 |  |  |
| | | from | 83 | | |
Abstract
Recently, one of the ultimately severe illnesses is the acute ischemic stroke which is now ranking as the fifth most common reason for morbidity and death in the US. In accordance to several reports, this disorder mainly claims the one life from each 20 people. Also, a stroke might claim the one person’s life every 4 minutes.
Neurological investigation along with an accurate taking of history lead to a timely diagnosis, but para-clinical and radiological evaluation also have a significant part in the diagnosis, prognosis, and outcome predictions. The serum biomarker might have a role in a number of facets of the stroke topic, from diagnosis to outcome prediction, and advanced examination is now being done in this area.
Neuron-Specific Enolase (NSE) is considered the one that is most likely given attention. NSE is an enzyme of a glycolytic nature that catalyzes glycolysis and is mainly found in the neuronal, neuroendocrine, and cerebrospinal fluid tissues.
In acute ischemic stroke patients, many research has demonstrated a positive link between NSE levels and infarct sizes. Meanwhile, few other investigations have not reveal such a relationship.
Multiple accumulating evidence from previous studies showed that upon admission the NSE levels and the stroke severity are significantly correlated. However, few researchers have discovered no such link between NSE levels and the severity of the stroke upon admission. There has also been significant interest in the capacity of neuron specific enolase levels to predict functional neurological results in stroke patients, with some research indicating that NSE is effective in predicting functional result and other studies indicating the opposite.